SG11201906414VA - Calicheamicin derivatives and antibody drug conjugates thereof - Google Patents
Calicheamicin derivatives and antibody drug conjugates thereofInfo
- Publication number
- SG11201906414VA SG11201906414VA SG11201906414VA SG11201906414VA SG11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- connecticut
- street
- avenue
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 5
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical class C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000220010 Rhode Species 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449839P | 2017-01-24 | 2017-01-24 | |
| PCT/IB2018/050153 WO2018138591A1 (en) | 2017-01-24 | 2018-01-10 | Calicheamicin derivatives and antibody drug conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906414VA true SG11201906414VA (en) | 2019-08-27 |
Family
ID=61168135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906414VA SG11201906414VA (en) | 2017-01-24 | 2018-01-10 | Calicheamicin derivatives and antibody drug conjugates thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11993625B2 (https=) |
| EP (1) | EP3573995A1 (https=) |
| JP (1) | JP7078405B2 (https=) |
| KR (1) | KR20190111086A (https=) |
| CN (1) | CN110461860A (https=) |
| AU (1) | AU2018211561B2 (https=) |
| BR (1) | BR112019015069A2 (https=) |
| CA (1) | CA3051038C (https=) |
| IL (1) | IL268245A (https=) |
| MX (1) | MX2019008773A (https=) |
| RU (1) | RU2732568C1 (https=) |
| SG (1) | SG11201906414VA (https=) |
| TW (1) | TWI687221B (https=) |
| WO (1) | WO2018138591A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2019008773A (es) * | 2017-01-24 | 2019-09-18 | Pfizer | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. |
| EP3720504A1 (en) * | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| EP3976112A1 (en) * | 2019-06-03 | 2022-04-06 | Synaffix B.V. | Acetal-based cleavable linkers |
| GB2585102B (en) | 2019-10-09 | 2021-06-30 | Audio Inventions Ltd | System for identification of a note played by a musical instrument |
| WO2025151608A1 (en) * | 2024-01-10 | 2025-07-17 | Systimmune, Inc. | Connecting units for ligand-drug conjugates and methods of making and using thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| ES2061586T3 (es) * | 1987-10-30 | 1994-12-16 | American Cyanamid Co | Analogos disulfuricos de agentes antitumorales ll-e33288. |
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| WO2005009882A1 (en) * | 2003-06-27 | 2005-02-03 | Otis Elevator Company | Absolute positioning system for elevators using dual encoders |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| WO2012007896A1 (en) | 2010-07-12 | 2012-01-19 | Covx Technologies Ireland, Ltd. | Multifunctional antibody conjugates |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| MX340090B (es) | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| US9453508B2 (en) | 2013-02-25 | 2016-09-27 | Asmo Co., Ltd. | Electric oil pump and hydraulic pressure supply device |
| KR101614151B1 (ko) | 2014-07-01 | 2016-04-22 | 한국화학연구원 | 흡입 독성 시험용 폐 모델 장치 |
| ES2797754T3 (es) | 2014-08-28 | 2020-12-03 | Pfizer | Enlazadores moduladores de la estabilidad para su uso con conjugados de fármaco y anticuerpo |
| EP3365025B1 (en) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
| WO2017172907A1 (en) | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
| WO2018069851A2 (en) | 2016-10-11 | 2018-04-19 | Sorrento Therapeutics, Inc. | C-met antibody drug conjugate |
| MX2019008773A (es) * | 2017-01-24 | 2019-09-18 | Pfizer | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. |
-
2018
- 2018-01-10 MX MX2019008773A patent/MX2019008773A/es unknown
- 2018-01-10 KR KR1020197024719A patent/KR20190111086A/ko not_active Withdrawn
- 2018-01-10 CA CA3051038A patent/CA3051038C/en active Active
- 2018-01-10 WO PCT/IB2018/050153 patent/WO2018138591A1/en not_active Ceased
- 2018-01-10 BR BR112019015069-2A patent/BR112019015069A2/pt not_active Application Discontinuation
- 2018-01-10 CN CN201880020707.5A patent/CN110461860A/zh active Pending
- 2018-01-10 EP EP18703623.1A patent/EP3573995A1/en active Pending
- 2018-01-10 AU AU2018211561A patent/AU2018211561B2/en not_active Ceased
- 2018-01-10 SG SG11201906414VA patent/SG11201906414VA/en unknown
- 2018-01-10 RU RU2019123161A patent/RU2732568C1/ru active
- 2018-01-10 US US16/477,290 patent/US11993625B2/en active Active
- 2018-01-22 JP JP2018008065A patent/JP7078405B2/ja active Active
- 2018-01-23 TW TW107102314A patent/TWI687221B/zh not_active IP Right Cessation
-
2019
- 2019-07-24 IL IL268245A patent/IL268245A/en unknown
-
2024
- 2024-04-05 US US18/627,949 patent/US20240409573A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018211561B2 (en) | 2020-04-30 |
| EP3573995A1 (en) | 2019-12-04 |
| JP7078405B2 (ja) | 2022-05-31 |
| CA3051038C (en) | 2022-07-26 |
| TW201838632A (zh) | 2018-11-01 |
| US20240409573A1 (en) | 2024-12-12 |
| JP2018123122A (ja) | 2018-08-09 |
| CA3051038A1 (en) | 2018-08-02 |
| WO2018138591A1 (en) | 2018-08-02 |
| AU2018211561A1 (en) | 2019-07-18 |
| KR20190111086A (ko) | 2019-10-01 |
| IL268245A (en) | 2019-09-26 |
| BR112019015069A2 (pt) | 2020-03-03 |
| CN110461860A (zh) | 2019-11-15 |
| RU2732568C1 (ru) | 2020-09-21 |
| MX2019008773A (es) | 2019-09-18 |
| TWI687221B (zh) | 2020-03-11 |
| US20190345186A1 (en) | 2019-11-14 |
| US11993625B2 (en) | 2024-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906414VA (en) | Calicheamicin derivatives and antibody drug conjugates thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201805375PA (en) | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201809301YA (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| SG11201908790PA (en) | Glucocorticoid receptor modulators to treat cervical cancer | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
| SG11201811161YA (en) | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201908159QA (en) | Dual magl and faah inhibitors |